Compare Abeona Therapeutics Inc (ABEO) vs DuPont de Nemours Inc (DD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs DuPont de Nemours Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while DuPont de Nemours Inc trades at $136.69 (market cap $18.85B). The key difference: DuPont de Nemours Inc is far larger — about 50.5× Abeona Therapeutics Inc's market cap, and DuPont de Nemours Inc pays a 1.72% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | DD | |
|---|---|---|
Market Cap | $373.32M | $18.85B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $154.59 |
52-Week Low | $4.17 | $87.72 |
Enterprise Value | $228.22M | $21.31B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
DuPont (DD) trades at $139.61, down 0.21% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten estimates, including Q1 2026 EPS of $1.65 versus $1.44 expected, though revenue declined to $6.85B in 2025. The company executed a 3:1 reverse stock split in June 2026 and maintains dividend payments, highlighting financial restructuring efforts amid mixed segment performance.
The outlook is cautiously optimistic with a consensus price target of $227.20, implying significant upside, but risks include persistent net losses, weak Q3 guidance concerns, and macroeconomic pressures on industrial segments. Investment appeal hinges on margin improvement and successful portfolio repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About DuPont de Nemours Inc
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.
Read more on DD →
